We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Studie EXSCEL - vliv exenatidu na kardiovaskulární bezpečnost.
- Authors
Vítovec, Jiří; Špinarová, Lenka
- Abstract
The EXSCEL clinical trail compared exenatide, a GLP-1 receptor agonist, and placebo among patients with type-2 diabetes with or without previous cardiovascular disease. The trial tested the safety hypothesis (non inferiority) and efficacy hypothesis (superiority). Exenatide, administered once weekly, was noninferior to placebo with respect to safety (P < 0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P = 0.06 for superiority).
- Publication
Intervencní a Akutní Kardiologie, 2018, Vol 17, Issue 3, p185
- ISSN
1213-807X
- Publication type
Article